Best GLP-1 Patches and Ozempic Alternatives for 2026: Industry Analysis Examines What Herbal Wellness Patches Actually Contain as New Year Weight Management Searches Surge Industry Report Examines What Consumers Are Searching For After Seeing Weight Loss Patch Ads, What These Products Actually Contain, and How to Evaluate Non-Prescription Options Entering 2026 NEW YORK, Dec
Food and Drug Administration approved the use of Wegovy to treat MASH in adults with excessive scar tissue in the liver
The ingredient formulation also excludes caffeine
In February 2025, the number of Ozempic lawsuit cases rose to 1,443, reflecting an increase of 112 cases compared to January 2025, where the total stood at 1,331
Other concerning symptoms that necessitate medical consultation include: Severe abdominal distension or inability to pass gas/stool (possible ileus or bowel obstruction) Nausea that worsens rather than improves after 812 weeks Inability to maintain adequate nutrition or hydration Unintentional weight loss exceeding clinical targets New or worsening heartburn or reflux symptoms Visual changes (especially with rapid blood sugar improvement) Severe headache or altered mental status Signs of gallbladder disease (right upper quadrant pain, especially after eating) Hypoglycemia symptoms if taking insulin or sulfonylureas Patients should generally not discontinue GLP-1 medications without medical guidance, except in emergencies such as suspected pancreatitis or severe allergic reaction